Mabel Ryder, MD
Endocrinology, Diabetes & Metabolism · Rochester, MNNPI 1083781215
Payments from drug & device makers
What this record shows
This record is dominated by education: $30 of the $30 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Ultragenyx Pharmaceutical Inc.. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MN, where the typical reported total is $238.
Across 1 payment — averaging $30.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ultragenyx Pharmaceutical Inc.$30
Across 7 payments — averaging $98,649 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$691K
- Corcept Therapeutics$40
What the payments were for
- Education$30100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
How this compares
$30 in reported general payments places this provider in the 10th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TafinlarDabrafenib Mesylate | 78 | $968,287 |
| MekinistTrametinib Dimethyl Sulfoxide | 65 | $793,443 |
| LenvimaLenvatinib Mesylate | 27 | $631,126 |
| RetevmoSelpercatinib | 32 | $484,989 |
| CabometyxCabozantinib S-Malate | 15 | $367,856 |
| GavretoPralsetinib | 21 | $277,736 |
| RozlytrekEntrectinib | 12 | $73,611 |
| Teriparatide | 14 | $32,011 |
| EliquisApixaban | 17 | $14,509 |
| LysodrenMitotane | 13 | $11,288 |
| Levothyroxine Sodium | 383 | $4,896 |
| SynthroidLevothyroxine Sodium | 38 | $4,389 |
| Calcitriol | 16 | $1,334 |
| LoperamideLoperamide Hcl | 13 | $950 |
| Ondansetron Hcl | 31 | $599 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Rochester
- Marjorie Ann MalbasRochester$222K
- Irina BancosRochester$114K
- Maria CastroRochester$63K
- Marius StanRochester$59K
- Matthew DrakeRochester$41K
- Manpreet MundiRochester$39K
- Yogish KudvaRochester$38K
- Bart ClarkeRochester$36K
- Robert RizzaRochester$30K
- Adrian VellaRochester$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.